deferoxamine and sorafenib

deferoxamine has been researched along with sorafenib in 2 studies

Research

Studies (2)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	2 (100.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K	1
Barbare, JC; Chauffert, B; Ezzoukhry, Z; Galmiche, A; Godin, C; Louandre, C; Mazière, JC	1

Reviews

1 review(s) available for deferoxamine and sorafenib

Article	Year
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans. Drug discovery today, 2016, Volume: 21, Issue:4 Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk	2016

Other Studies

1 other study(ies) available for deferoxamine and sorafenib

Article	Year
Iron-dependent cell death of hepatocellular carcinoma cells exposed to sorafenib. International journal of cancer, 2013, Oct-01, Volume: 133, Issue:7 Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Death; Cell Line, Tumor; Cell Survival; Cyclohexylamines; Deferoxamine; Extracellular Signal-Regulated MAP Kinases; Humans; Iron; Iron Regulatory Protein 2; Liver Neoplasms; MAP Kinase Kinase Kinases; MAP Kinase Signaling System; Niacinamide; Oxidative Stress; Phenylenediamines; Phenylurea Compounds; Protein Kinase Inhibitors; raf Kinases; RNA Interference; Siderophores; Sorafenib	2013

Article

Year

Iron-dependent cell death of hepatocellular carcinoma cells exposed to sorafenib.

International journal of cancer, 2013, Oct-01, Volume: 133, Issue:7

Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Death; Cell Line, Tumor; Cell Survival; Cyclohexylamines; Deferoxamine; Extracellular Signal-Regulated MAP Kinases; Humans; Iron; Iron Regulatory Protein 2; Liver Neoplasms; MAP Kinase Kinase Kinases; MAP Kinase Signaling System; Niacinamide; Oxidative Stress; Phenylenediamines; Phenylurea Compounds; Protein Kinase Inhibitors; raf Kinases; RNA Interference; Siderophores; Sorafenib

2013